ABBV
NYSE · Biotechnology
Abbvie Inc
$207.18
+1.98 (+0.96%)
Financial Highlights (FY 2026)
Revenue
55.26B
Net Income
4.20B
Gross Margin
70.0%
Profit Margin
7.6%
Rev Growth
+0.1%
D/E Ratio
20.19
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 70.0% | 70.0% | 41.9% | 41.9% |
| Operating Margin | 16.2% | 14.6% | 4.7% | 4.9% |
| Profit Margin | 7.6% | 7.2% | 3.7% | 3.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 55.26B | 55.21B | 206.54B | 154.58B |
| Gross Profit | 38.67B | 38.64B | 86.47B | 64.71B |
| Operating Income | 8.96B | 8.06B | 9.72B | 7.57B |
| Net Income | 4.20B | 3.77B | 7.53B | 5.59B |
| Gross Margin | 70.0% | 70.0% | 41.9% | 41.9% |
| Operating Margin | 16.2% | 14.6% | 4.7% | 4.9% |
| Profit Margin | 7.6% | 7.2% | 3.7% | 3.6% |
| Rev Growth | +0.1% | +0.1% | +21.3% | +19.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 189.50B | 189.50B | 60.07B | 57.45B |
| Total Equity | 9.38B | 9.38B | 267.56B | 258.44B |
| D/E Ratio | 20.19 | 20.19 | 0.22 | 0.22 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 6.53B | 6.20B | 15.67B | 11.30B |
| Free Cash Flow | — | — | 10.35B | 8.18B |